The ever-growing global diabetes burden is an uphill battle for drug manufacturers. Insulin serves as the go-to drug in the treatment of diabetes when all others fail. The development of this drug has matured with time into more purified human formulations from the older bovine and porcine preparations, as well as the newer available analogues, which give greater flexibility from ultra-short acting to long-acting basal formulations. Short or rapid-acting insulins predominantly focus on the prandial sugar spikes, while the longer-acting and basal insulins work on the fasting glucose levels. Prandial or short-acting insulins are administered with the number of meals taken; while the basal insulin is taken once daily, usually at bedtime and works for ≥24 hours. However, this still warrants the basal insulin to be taken every 24 hours. In this article, we focus on a newer formulation of insulin that is proposed to act for a week, thereby reducing the number of injection jabs considerably and contributing towards increased patient compliance. This would translate to better HbA1c reduction and curb the onset of both micro- and macro-vascular complications seen in diabetes.
References
[1]
International Diabetes Federation (2025) Facts & Figures. https://idf.org/about-diabetes/diabetes-facts-figures/
[2]
Zhou, B., Rayner, A.W., Gregg, E.W., Sheffer, K.E., Carrillo-Larco, R.M., Bennett, J.E., et al. (2024) Worldwide Trends in Diabetes Prevalence and Treatment from 1990 to 2022: A Pooled Analysis of 1108 Population-Representative Studies with 141 Million Participants. The Lancet, 404, 2077-2093. https://doi.org/10.1016/s0140-6736(24)02317-1
[3]
Boyle, J.P., Honeycutt, A.A., Narayan, K.M.V., Hoerger, T.J., Geiss, L.S., Chen, H., et al. (2001) Projection of Diabetes Burden through 2050. Diabetes Care, 24, 1936-1940. https://doi.org/10.2337/diacare.24.11.1936
[4]
Quianzon, C.C. and Cheikh, I. (2012) History of Insulin. Journal of Community Hospital Internal Medicine Perspectives, 2, Article 18701. https://doi.org/10.3402/jchimp.v2i2.18701
[5]
American Diabetes Association (2020) 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021. Diabetes Care, 44, S111-S124. https://doi.org/10.2337/dc21-s009
[6]
Ranganath, L.R. (2008) The Entero-Insular Axis: Implications for Human Metabolism. Clinical Chemistry and Laboratory Medicine, 46, 43-56. https://doi.org/10.1515/cclm.2008.008
[7]
Grunberger, G., Chang, A., Garcia Soria, G., Botros, F.T., Bsharat, R. and Milicevic, Z. (2012) Monotherapy with the Once‐Weekly GLP‐1 Analogue Dulaglutide for 12 Weeks in Patients with Type 2 Diabetes: Dose‐Dependent Effects on Glycaemic Control in a Randomized, Double‐Blind, Placebo‐Controlled Study. Diabetic Medicine, 29, 1260-1267. https://doi.org/10.1111/j.1464-5491.2012.03745.x
[8]
Thomas, J.J. (2025) Twincretin (Dual GIP/GLP-1 Receptor Agonists): The New Kid on the Block. Journal of Diabetes and Treatment, 10, Article 10139. https://doi.org/10.29011/2574-7568.010139
[9]
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., et al. (2015) Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry, 58, 7370-7380. https://doi.org/10.1021/acs.jmedchem.5b00726
[10]
Thomas, J.J., et al. (2025) Inhaled Insulin: A Much-Needed Needleless Paradigm Shift in Diabetes Management. Journal of Diabetes and Treatment, 10, Article 10140. https://doi.org/10.29011/2574-7568.010140
[11]
Wronkowitz, N., Hartmann, T., Görgens, S.W., Dietze‐Schroeder, D., Indrakusuma, I., Choi, I.Y., et al. (2017) LAPSInsulin115: A Novel Ultra‐Long‐Acting Basal Insulin with a Unique Action Profile. Diabetes, Obesity and Metabolism, 19, 1722-1731. https://doi.org/10.1111/dom.13006
[12]
Bue-Valleskey, J.M., Kazda, C.M., Ma, C., Chien, J., Zhang, Q., Chigutsa, E., et al. (2023) Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients with Type 2 Diabetes: A Phase 2 Randomized Control Trial. Diabetes Care, 46, 1060-1067. https://doi.org/10.2337/dc22-2396
[13]
Frias, J., Chien, J., Zhang, Q., Chigutsa, E., Landschulz, W., Syring, K., et al. (2023) Safety and Efficacy of Once-Weekly Basal Insulin Fc in People with Type 2 Diabetes Previously Treated with Basal Insulin: A Multicentre, Open-Label, Randomised, Phase 2 Study. The Lancet Diabetes & Endocrinology, 11, 158-168. https://doi.org/10.1016/s2213-8587(22)00388-6
[14]
Kazda, C.M., Bue-Valleskey, J.M., Chien, J., Zhang, Q., Chigutsa, E., Landschulz, W., et al. (2023) Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control with a Safety Profile Comparable to Insulin Degludec in Patients with Type 1 Diabetes. Diabetes Care, 46, 1052-1059. https://doi.org/10.2337/dc22-2395
[15]
Argano, C., Priola, L., Manno, F. and Corrao, S. (2024) What Is the Role of Basal Weekly Insulin in Clinical Practice? The State of the Art. Biomedicines, 12, Article 900. https://doi.org/10.3390/biomedicines12040900
[16]
Rosenstock, J., Bain, S.C., Gowda, A., Jódar, E., Liang, B., Lingvay, I., et al. (2023) Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. New England Journal of Medicine, 389, 297-308. https://doi.org/10.1056/nejmoa2303208
[17]
Philis-Tsimikas, A., Asong, M., Franek, E., Jia, T., Rosenstock, J., Stachlewska, K., et al. (2023) Switching to Once-Weekly Insulin Icodec versus Once-Daily Insulin Degludec in Individuals with Basal Insulin-Treated Type 2 Diabetes (ONWARDS 2): A Phase 3a, Randomised, Open Label, Multicentre, Treat-to-Target Trial. The Lancet Diabetes & Endocrinology, 11, 414-425. https://doi.org/10.1016/s2213-8587(23)00093-1
[18]
Lingvay, I., Asong, M., Desouza, C., Gourdy, P., Kar, S., Vianna, A., et al. (2023) Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults with Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial. JAMA, 330, 228-237. https://doi.org/10.1001/jama.2023.11313
[19]
Mathieu, C., Ásbjörnsdóttir, B., Bajaj, H.S., Lane, W., Matos, A.L.S.A., Murthy, S., et al. (2023) Switching to Once-Weekly Insulin Icodec versus Once-Daily Insulin Glargine U100 in Individuals with Basal-Bolus Insulin-Treated Type 2 Diabetes (ONWARDS 4): A Phase 3a, Randomised, Open-Label, Multicentre, Treat-to-Target, Non-Inferiority Trial. The Lancet, 401, 1929-1940. https://doi.org/10.1016/s0140-6736(23)00520-2
[20]
Bajaj, H.S., Aberle, J., Davies, M., Donatsky, A.M., Frederiksen, M., Yavuz, D.G., et al. (2023) Once-Weekly Insulin Icodec with Dosing Guide App versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5). Annals of Internal Medicine, 176, 1476-1485. https://doi.org/10.7326/m23-1288
[21]
Russell-Jones, D., Babazono, T., Cailleteau, R., Engberg, S., Irace, C., Kjaersgaard, M.I.S., et al. (2023) Once-weekly Insulin Icodec versus Once-Daily Insulin Degludec as Part of a Basal-Bolus Regimen in Individuals with Type 1 Diabetes (ONWARDS 6): A Phase 3a, Randomised, Open-Label, Treat-to-Target Trial. The Lancet, 402, 1636-1647. https://doi.org/10.1016/s0140-6736(23)02179-7
[22]
Wang, P., Zhang, Y., Xu, W., He, J., Peng, L., Feng, Y., et al. (2024) Efficacy and Safety of Once-Weekly Insulin Regimes on Glycemic Control for Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetology & Metabolic Syndrome, 16, Article No. 3. https://doi.org/10.1186/s13098-023-01240-5
